In Vitro Fertilization Market Share, Growth And Trends Analysis By Type (Intrauterine Insemination, Intracytoplasmic Sperm Injection, Ivf Using Donor Eggs), By Devices (Imaging Systems, Sperm Separation System, Ovum Aspiration Pump, Micromanipulator, Cryosystem) By Reagents (Embryo Culture Media, Cryopreservation Media, Sperm Processing Media, Ovum Processing Media), By End Users (Clinical Research Institutes, Fertility Clinics, Hospitals) - Forecast to 2027

The global in-vitro fertilization (IVF) devices market is projected to witness growth at a CAGR of 10.50% during the forecast period from 2018 to 2023. In-vitro fertilization has become highly popular for its use in the treatment of fertility problems and is often used as the last effort to induce a natural pregnancy. It provides prospective parents the opportunity to have a biological child or can be used to ensure that serious genetic disorders are not passed on to their child. In 2017, the global in-vitro fertilization devices market was valued at USD 6,984.3 Mn, the imminent growth of the market is expected to result in a market value of approximately USD 12,714 Mn by the end of 2023.

Infertility has become a significant issue affecting a considerable portion of the population. The Center for Disease Control & Prevention has found that close to 7.4 Mn women in the US have been recorded as having difficulty conceiving and/or maintaining pregnancy. In the UK the statistics reflect that 1 in 7 couples have trouble conceiving. Several factors have been identified such as low sperm count, inability to form eggs, and several others. IVF techniques have been successfully implemented in such cases to treat infertility; this has increased the demand and use of IVF. Moreover, the increasing demand for infertility treatments has led to increased development of new technologies which offer the highest rate for success. This is particularly significant due to the high cost of IVF treatment.

Although IVF treatments have become adopted widely, the high costs associated with fertility treatments is expected to hamper market growth. In the US, the average cost of one IVF treatment with the exception of required prescription medication is over USD 12,000. Although these figures vary from region to region, they are still fairly expensive and unaffordable. To address this, there is a growing availability of funding and reimbursements for certain in-vitro fertilization treatments which are expected to provide the market with opportunity for growth.

The global in-vitro fertilization devices market is segmented on the basis of product, type, end-user, and region. In-vitro fertilization products are broadly segmented into devices and reagents. Devices are further sub-segmented into imaging systems, sperm separation system, cerosystem, micromanipulator and ovum aspiration pump. Reagents are sub-segmented into cryopreservation media, sperm processing media, ovum processing media, and embryo culture media. Devices account for the most significant share of the market and valued USD 3,739.7 in 2017 due to the increased use of imaging systems in IVF treatments. Moreover, the devices segment is expected to grow at the highest CAGR during the forecast period.

Various types of in-vitro fertilization include intrauterine insemination (IUI), in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and IVF using donor eggs. The IUI segment around for the largest share of the market and is generally preferred as it is minimally invasive and has a good success rate. Meanwhile, the IVF segment is expected to witness the highest growth at a CAGR of 11.68% during the forecast period. End users of IVF methods include fertility clinics, hospitals, clinical research centers, and others. The fertility clinics segment accounts for the largest segment in the market. The hospital segment is the second largest and is expected to grow at the highest CAGR of 12.92%; hospitals have increased service offerings for infertility problems, thus the segments rapid growth.

Regional Analysis

Europe has the most significant share of the global IVF devices market. Government support for research and development activities, the presence of well-established healthcare infrastructure and the high budget for health care expenses are among the key factors driving the growth of the market. European market growth is primarily led by Western Europe countries which include Germany, the UK, and France. The Europe IVF devices market is expected to witness a CAGR of 10.94% during the forecast period.

The Americas IVF devices market account for the second largest regional segment. The region has a high concentration of leading players, and a high adoption rate of advanced technologies which has contributed significantly toward the development of the market. North America leads the Americas IVF devices market. The Asia Pacific is the fastest growing regional market with the highest CAGR during the forecast period. The region has a high demand and requirement for advanced diagnostic methods. The rapidly changing healthcare sector poses huge opportunities for the development of the market.

Meanwhile, the Middle East and Africa has the smallest share of the market which is expected to grow at the lowest CAGR. This is primarily due to the region’s inclusion of the African continent which has a high concentration of under-developed economies with a high requirement for basic healthcare.

Competitive Tracking

The global in-vitro fertilization devices market is fragmented and includes a number of small regional clinics. The report, however, profiles prominent players such as Cook Medical, Cooper Surgical Fertility, Merck KGaA, Thermo Fisher Scientific, INVO Bioscience, Irvine Scientific, GENEA BIOMEDIX, Vitrolife, Oxford Gene Technology, and Genea Limited. These players primarily use product approval, expansion, strategic acquisitions and partnerships as key competitive strategies which influence growth.

Global In-vitro Fertilization Market: Competitive Landscape

The prominent players in the global in-vitro fertilization market are Cook Medical, Irvine Scientific Sales Company, Inc., Cooper Surgical, Merck KGaA, and others.

Cooper Surgical Fertility (Origio) accounted for the largest market share of the global in-vitro fertilization market, with around 25.4% of the market share in 2017. The large share of the company is attributed to innovative products that address a wide range of patients with infertility. Moreover, Cooper Surgical Fertility is focusing on bringing health and wellness to individuals and communities worldwide. A Cooper Surgical Fertility Company is committed to advancing the health of families with its diversified portfolio of products and services to mainly focus on women health, fertility, and diagnostic products. It targets specific difficult-to-cure diseases with the help of its core R&D expertise.

Vitrolife accounts for approximately 21.7% share in the in-vitro fertilization market owing to a wide range of product portfolio. Vitrolife provides a high quality of IVF laboratories product in the market. The company has production facilities in more than ten countries globally.

Cook Medical holds the third largest position in the global in-vitro fertilization market with a 16.2% market share. Irvine Scientific holds the fourth largest position in the global in-vitro fertilization market with a market share of 10.5%. Cook Medical is the spin-off of Abbott Laboratories and was formed in 2013 and therefore has more than 100 years of legacy. Abbott Laboratories company operates through four reportable segments, namely, established pharmaceutical products, diagnostic products, nutritional products, and vascular products. Furthermore, the company has two non-reportable segments, namely, diabetes care and medical optics. Cook Medical is a highly focused research-driven biopharmaceutical company. It targets specific difficult-to-cure diseases with the help of its core R&D expertise.

Irvin Scientific is focusing on innovation and development of cell culture media, reagents, and medical devices for researchers. Irvin Scientific provides unrivaled services and products to scientists working on cell therapy, assisted reproductive technology, and industrial cell culture to produce biopharmaceuticals and vaccines. It targets specific difficulties to cure diseases with the help of its core R&D expertise. Irvin Scientific has remained focused on media while becoming a global leader in media products and services.

Thermo Fisher Scientific Inc. specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, specialty diagnostics, and others. Ortho Clinical Diagnostics (Part of Johnson & Johnson Services Inc.) is serving the global clinical laboratory and immunohematology communities across hospitals, hospital networks, blood banks, and labs in more than 120 countries. The company specializes in in-vitro diagnostics, clinical labs, transfusion medicine, and immunohematology.

Merck KGaA is focusing on bringing health and wellness to individuals’ communities worldwide.  Merck KGaA is committed to advancing the health of families with its diversified portfolio of products and services to mainly focus on women health, fertility, and diagnostic products. Merck KGaA is a leading pharmaceutical company which has a varied range of products sub-segmented into healthcare, life science, and performance material.